24 . 10 .2024
Press release
Galderma delivers record net sales of 3.259 B USD in the first nine months of 2024, demonstrates significant innovation progress, confirms and narrows its full year net sales guidance
13 . 08 .2024
Press release
Galderma receives U.S. FDA approval for Nemluvio® (nemolizumab) for adult patients living with prurigo nodularis
05 . 08 .2024
Press release
Galderma to pursue a new scientific partnership with L’Oréal to further advance its category leadership in dermatology
30 . 07 .2024
Press release
Galderma’s Relfydess™ (RelabotulinumtoxinA) receives positive decision for use in Europe
25 . 07 .2024
Press release
Galderma delivers record net sales of 2.2 billion USD and 10.8% year-on-year growth at constant currency for the first half of 2024
24 . 04 .2024
Press release
Galderma delivers a strong start to the year with record net sales of over 1 billion USD for the first quarter and 12.4% year-on-year growth
